Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 5Sarcoma 2Thoracic 1Plasma cell 1Lymphoid 1Head & Neck 1Gynecologic 1Breast 1

Conditions

Neoplasm Metastasis 1Endometrial Neoplasms 1

Interventions

Paclitaxel 77pembrolizumab 59Carboplatin 57Bevacizumab 57Specimen Handling 48Magnetic Resonance Spectroscopy 39Cisplatin 32olaparib 31Gemcitabine 25liposomal doxorubicin 24Biopsy 20Taxes 19Topotecan 17Nivolumab 17Cyclophosphamide 16Immunoglobulin G 15Doxorubicin 15Disulfides 15niraparib 12fludarabine 12Surveys and Questionnaires 12Letrozole 12lenvatinib 11durvalumab 11atezolizumab 11Fulvestrant 10Drug Therapy 10abemaciclib 9Docetaxel 9Brachytherapy 9

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
futibatinib × Gynecologic × 90 days × Clear all
NCT05036681 2026-03-27

A Phase II Study of Futibatinib and Pembrolizumab in Metastatic Microsatellite Stable Endometrial Carcinoma

M.D. Anderson Cancer Center

Phase 2 Terminated
9 enrolled 10 charts
Gynecologic

Neoplasm Metastasis, Endometrial Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡